This review explores the neurobiological mechanisms of bremelanotide, a melanocortin receptor (MCR) agonist, in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide activates MC4Rs in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release and enhancing sexual desire. The review discusses how neurotransmitters like norepinephrine and
